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Abstract
Background: Autism Spectrum Disorder (ASD) is a severe, lifelong neurodevelopmental disorder with early onset
that places a heavy burden on affected individuals and their families. Due to the need for highly specialized health,
educational and vocational services, ASD is a cost-intensive disorder, and strain on health care systems increases
with increasing age of the affected individual.
Methods: The ASD-Net will study Germany’s largest cohort of patients with ASD over the lifespan. By combining
methodological expertise from all levels of clinical research, the ASD-Net will follow a translational approach
necessary to identify neurobiological pathways of different phenotypes and their appropriate identification and
treatment. The work of the ASD-Net will be organized into three clusters concentrating on diagnostics, therapy and
health economics. In the diagnostic cluster, data from a large, well-characterized sample (N = 2568) will be analyzed
to improve the efficiency of diagnostic procedures. Pattern classification methods (machine learning) will be used
to identify algorithms for screening purposes. In a second step, the developed algorithm will be tested in an
independent sample. In the therapy cluster, we will unravel how an ASD-specific social skills training with
concomitant oxytocin administration can modulate behavior through neurobiological pathways. For the first
time, we will characterize long-term effects of a social skills training combined with oxytocin treatment on
behavioral and neurobiological phenotypes. Also acute effects of oxytocin will be investigated to delineate
general and specific effects of additional oxytocin treatment in order to develop biologically plausible models
for symptoms and successful therapeutic interventions in ASD. Finally, in the health economics cluster, we will
assess service utilization and ASD-related costs in order to identify potential needs and cost savings specifically
tailored to Germany. The ASD-Net has been established as part of the German Research Network for Mental
Disorders, funded by the BMBF (German Federal Ministry of Education and Research).
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Discussion: The highly integrated structure of the ASD-Net guarantees sustained collaboration of clinicians and
researchers to alleviate individual distress, harm, and social disability of patients with ASD and reduce costs to
the German health care system.
Trial registration: Both clinical trials of the ASD-Net are registered in the German Clinical Trials Register:
DRKS00008952 (registered on August 4, 2015) and DRKS00010053 (registered on April 8, 2016).
Keywords: Autism spectrum disorder, Screening, Diagnosis, Therapy, Social competence training, Oxytocin,
Health economics, Genetic, ASD-net, German research network for mental disorders
Background
The German Federal Ministry of Education and
Research is funding a new research network from 2015
to 2019, providing up to 35 million Euros to investigate
mental disorders with the aim of devising and develop-
ing better diagnostic and therapeutic measures and
strategies for the country’s population by means of
basic and translational clinical research. Resulting from
a competitive call for research proposals entitled
“German Research Network for Mental Disorders”, a
network of expert consortia from largely university-
based research facilities for children, adolescents and/
or adults was established. Each consortium will focus
its research on one psychiatric disorder, including autism
spectrum disorder, anxiety disorders, attention deficit
hyperactivity disorder (ADHD), bipolar disorder, depres-
sion, schizophrenia and psychotic disorder and substance-
related and addictive disorders [1]. Three cross-consortia
platform projects will seek to identify shared causes of dis-
eases and develop new diagnostic modalities for this
multitude of mental disorders [1]. The present contribu-
tion outlines the study protocol for the consortium for
Autism Spectrum Disorder, the ASD-Net.
Autism spectrum disorder (ASD)
ASD is a severe, lifelong and highly cost-intensive neuro-
developmental disorder characterized by impairments in
social interaction (e.g. deficits in appropriate eye contact,
facial expression, emotion perception, gesture, social and
emotional reciprocity) and communication (e.g. echola-
lia, stereotyped language, reduced reciprocal conversa-
tion), as well as restricted and repetitive behavior (e.g.
rigid preferences for routines, repetitive motor man-
nerisms) [2, 3]. For decades, ASD was believed to occur
in 4 to 5 per 10,000 children. Nowadays, the prevalence
of ASD is estimated at 1% in children and adolescents
[4, 5] as well as adults [6], making ASD as common as
major psychiatric disorders, e.g. schizophrenia. Al-
though ASD is often considered a childhood disorder,
it persists throughout the lifespan [7]. The psychosocial
impairment of individuals with ASD is well known [8].
Affected individuals often show severe difficulties in
interpersonal relationships and live socially isolated.
Since their adaptive behavior, the ability to function
independently, seems to fall short of their cognitive
capacities, individuals with ASD suffer from consider-
able impairment in everyday life [9, 10]. Despite good
school and/or occupational education, many individ-
uals with ASD are significantly disadvantaged in terms
of employment, social relationships, and physical as
well as mental health in their later years [11]. As a con-
sequence, they experience frequent job changes and
report diminished overall quality of life [12, 13]. Sup-
port to facilitate integration into society (e.g. through
specialized rehabilitation services) is frequently lacking,
and there has been almost no research into ways of
developing more effective intervention programs for
adolescents and adults with ASD [14, 15]. Besides
demonstrating the detrimental impact of ASD on gen-
eral well-being, recent research shows an increased
prevalence of psychiatric comorbidities, e.g. emotional
disorders, depression or ADHD [11, 16–21] as well as
other medical comorbidities [22, 23]. This may lead to
an increased burden upon families living with an ASD
affected child [24, 25].
Etiological background
In the expression and severity of core and associated
ASD symptoms, a considerable heterogeneity is observed
[26, 27]. Obvious particularly in the social interaction
domain, variability ranges from a near absence of inter-
est in social interaction to rather subtle difficulties in
managing complex social interactions that require an
understanding of other people’s beliefs, intentions or
goals and other cues of social context. Further factors
such as developmental trajectories, gender, level of lan-
guage, cognitive functioning, adaptive behavior, comor-
bidities etc. contribute to the considerable heterogeneity
of the disorder. Although ASD is a strongly genetically
determined disorder with a heritability of up to 90%
[28–31], the phenotypic variability is paralleled by a
notable genetic heterogeneity [for review see: [32–34].
In the past decade, various ASD susceptibility genes
and associated biologically coherent functional path-
ways have been explored [33]. However, many different
genetic patterns are also associated with other
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psychiatric disorders [32, 33, 35, 36]. Therefore, it is of
crucial importance to elucidate the link between
specific genetic risk variants including epigenetic mech-
anisms and impaired neural circuitry underlying deficits
in the social interaction domain in ASD [33, 37] (e.g.
deficits in Theory of Mind, empathy [38–41] and social
motivation [42–46]).
Diagnosis
Over the past 30 years, the awareness of ASD has in-
creased remarkably, both in public consciousness and in
the health professions. This is manifested, for instance,
by the large numbers of children, adolescents and specif-
ically adults who present with a suspected diagnosis of
ASD, reflecting the increasing demand for diagnosis and
treatment by skilled clinicians. Existing screening instru-
ments for autistic symptoms do, in fact, identify individ-
uals with ASD accurately, but fail to discriminate
individuals with ASD from those with other psychiatric
disorders and complex neurobehavioral profiles (such as
ADHD, emotional and personality disorders and others),
especially in high-functioning individuals [47–55]. The
so-called gold standard clinical tools comprise a stan-
dardized interview (Autism Diagnostic Interview Re-
vised, ADI-R), combined with a standardized behavior
observation (Autism Diagnostic Observation Schedule-
Generic, ADOS-G) and a differential diagnostic examin-
ation (requiring up to six hours altogether). Specialized
training is needed to become proficient in administering
these instruments. Validation studies of these ASD-
specific instruments for adults are sparse.
In conclusion, a main issue in health care services is
the correct and economical decision on who does or
does not require a time- and cost-intensive expert diag-
nosis for ASD. More trained specialized clinicians and
quality management of the diagnostic process are
needed to maintain diagnostic quality, improve health
services and avoid severe comorbid disorders and socio-
economic burden.
Therapy
Although ASD is considered a neurobiological disorder,
primary treatments nowadays consist of psychological
and educational interventions to address the core defi-
cits related to the disorder. To date, the best empirical
evidence exists for early intensive behavioral interven-
tion (EIBI) applying the principles of applied behavior
analysis [56]; however, studies on the effectiveness of
social skills group training have seen a recent increase,
especially for adolescents with average and above-
average cognitive skills [57]. Randomized controlled
trials (RCTs) using stringent inclusion and exclusion cri-
teria provide evidence that social skills training (SST) is
moderately effective in improving social competence and
decreasing loneliness in children and adolescents with
ASD [58]. Little is known however, about the potentially
enhancing effect of additional oxytocin (OXT) treatment
along with SST on the acquisition of social competence
in ASD. While a growing number of studies show the ef-
ficacy of behavior-based interventions in ASD, research
on the combination of psychotherapeutic interventions
and concomitant pharmacological treatment strategies is
still sparse. To date, only a small body of research sup-
ports the notion that administration of additional medi-
cation may have the potential to enhance effects of
psychotherapeutic/behavioral therapies. Since OXT has
been identified as a powerful enhancer of neural activity
related to social cognition, the formation of social bonds
and socially reinforced learning [59–62] it is of particular
relevance for ASD and its treatment options. In the last
decade, a rapidly growing number of interdisciplinary
(pharmacokinetics, (epi)genetics, neuroimaging, imaging
genetics, clinical) studies have consistently indicated that
OXT plays an important role in modulating human so-
cial behavior with translational relevance for under-
standing ASD [for review see: [63]].
Pioneering but strong evidence suggests that OXT
has the potential to enhance motivation and attention
to social cues in patients with ASD [62], facilitating the
processing of affiliative emotions, social reward and
higher cognitive functions such as empathy and Theory
of Mind (ToM) in the long term. A recently published
review and a meta-analysis [63, 64] summarizing the
potentials and limitations of pharmacotherapeutic ap-
plications of OXT, came to the conclusion that studies
on ASD did show significant effect sizes and that more
sophisticated and targeted clinical trials were required.
Beyond a therapy augmenting effect, it has been dem-
onstrated that (epi)genetic factors (e.g., methylation dif-
ferences) influence an individuals’s response to OXT,
either by directly acting on OXT genes or via the regu-
lation of genes in pathways related to OXT [65, 66].
Accordingly, genotypic effects are inconsistent [67] and
epigenetic factors have to be taken into account to
identify those that contribute to the acute and long-
term effects of intranasal OXT.
In summary, cumulative evidence regarding OXT
treatment clearly indicates its effectiveness in modulat-
ing social behavior and the neural processing of social
stimuli in healthy individuals. Several studies on ASD
highlight the therapeutic potential of intranasal OXT
through effects on core dimensions of social cognition
and affected brain systems. However, the exact neural
processes, the specificity of this effect for the social
domain, and the interaction between different neural
networks and neurotransmitter systems still remain to
be determined. There is no doubt that a complex dis-
order such as ASD requires a multifaceted treatment
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approach. As ASD is a predominantly neurobiologically
determined disorder, neurobiological-based approaches,
alongside behavior-based methods, should be consid-
ered in the treatment of ASD. Moreover, as ASD is a
highly heterogeneous disorder, the prediction of treat-
ment response in different subtypes of ASD should be
included in well-designed intervention studies in order to
correctly allocate individuals to treatment settings [15].
Health service utilization and costs
In recent years, the reported prevalence of ASD has
increased markedly in Western countries, including
Germany [68]. As a consequence, the demand on ASD-
specific health services has risen, and there is a need for
an improved understanding of adequate diagnostic and
therapeutic pathways for these patients. Pathways to an
ASD diagnosis are often time-consuming and compli-
cated, with perceived stigma being a potential barrier
[69]. Suboptimal pathways to ASD diagnosis can result
in dissatisfaction in the carers of patients with ASD, and
might preclude timely and adequate treatment of the
condition [70]. According to data from the UK and the
US, lifetime direct (medical and non-medical) and indir-
ect costs per individual with ASD amount to 1.2–2.4
million USD [71]. The substantial burden of ASD on
health and social services has been shown to be greater
than that of other childhood illnesses such as diabetes,
asthma or intellectual disabilities [72]. ASD begins in
childhood, continues across the lifespan, and requires
complex and highly specialized health, educational, and
vocational services over many years. This burden is
compounded by out-of-pocket expenses, e.g. for comple-
mentary and alternative medicine (CAM) [73]. In con-
clusion, ASD is a cost-intensive disorder, with costs
increasing with age [74, 75]. Fortunately, these costs can
at least be countered by early behavioral interventions:
Data from the Netherlands demonstrate long-term sav-
ings of approximately € 1.1 million per individual with
ASD from early behavioral intervention. Extending these
costs to the whole Dutch ASD population, cost savings
of € 109–182 billion have been estimated [76]. Neverthe-
less, German data on ASD-related costs are lacking [77].
Aims
To address these urgent needs, broad competencies
and extensive experience in clinical and research issues
are required. Moreover, a comprehensive and well-
characterized cohort of patients, diagnosed with stan-
dardized procedures, is necessary. The ASD-Net fulfills
these prerequisites: it includes the largest ASD cohort
in Germany, consisting of patients diagnosed by the
gold standard of standardized diagnostic tools (ADOS,
ADI-R) including all age and IQ ranges and a signifi-
cant number of females diagnosed with ASD. The
ASD-Net seeks to establish a large clinical and
research network focusing on the key challenges in
ASD diagnostics, therapy and health economics. The
multidisciplinary ASD-Net brings together excellent expert-
ise in ASD, Germany’s largest cohorts in ADI-R−/ADOS-
diagnosed children, adolescents, and adults, and state-
of-the-art genetic and neurobiological research. The
work of the ASD-Net is organized into three clusters
concentrating on diagnostics, therapy and health eco-
nomics. The following research questions and assump-
tions are examined: Diagnostic cluster: Is it possible to
develop a reduced number of economical and valid
screening items for an early, sensitive and accurate detec-
tion of ASD? Therapy cluster: What are the acute and
long-term effects of OXT treatment in ASD? Does an ad-
junctive application of OXT treatment with SST show
promise in providing resources to the affected individuals
and their families? What are the mediators and modera-
tors of OXT treatment on the level of behavior, neural
networks, and (epi)genetics? It is hypothesized that there
are long-term synergistic effects of combining psycho-
therapeutic strategies (SST) with pharmacological treat-
ment (OXT). Furthermore, effects of SST are assumed
to be reflected in neurobiological changes in key brain
structures associated with ASD in general and with so-
cial cognition in particular. These changes are more
pronounced in patients receiving a combined treatment
with SST and OXT than in patients receiving SST and
placebo. Biomarkers are useful for indexing and pre-
dicting response to different treatment options in order
to assign specific treatment to ASD subgroups. Acute
OXT treatment in ASD stimulates neural network ac-
tivity underlying socio-affective and socio-cognitive
processes: OXT normalizes the way in which brain sys-
tems process (1) social anxiety and affiliative motivation
in ASD, (2) social reward, and (3) emotional empathy
as well as Theory of Mind. Health economics cluster:
What are the medical and non-medical costs of ASD in
Germany? Do age, IQ, socioeconomic status or gender
impact health and social service utilization and the as-
sociated costs? The assessment of service utilization
and costs in a very large German ASD cohort helps to
draw a naturalistic picture of ASD-related resource
utilization and economic consequences, which in turn
allows a modeling of potential changes induced by




Recently, pattern classification methods based on ma-
chine learning algorithms have been used to predict or
classify individuals of different phenotypes. The idea of
machine learning is to find structural patterns in a
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dataset, and to use these patterns to understand the data
and the interrelations of its elements. Thus, the aim of
machine learning is to train a computer algorithm to
identify complex pattern within a given dataset and to
apply the resulting classifier to new individuals to make
a better prediction concerning phenotype identification,
treatment outcome, and prognosis [78]. The main bene-
fit of pattern classification lies within its potential to
detect global, complex, and (in case of ASD) multimodal
patterns of abnormalities that can otherwise not be effi-
ciently identified [79]. Training usually takes place in a
well-characterized sample by finding an algorithm that
best discriminates between classes (ASD vs. non-ASD).
Once this algorithm is developed, it can subsequently be
used to predict group membership in an independent
sample. In order to identify those items of the applied
diagnostic tools which show the best discriminatory
quality these innovative approaches – already evaluated
in the domain of ASD diagnosis in three pilot studies
[80–82] – will be applied to the data of 2568 children,
adolescents and adults. Retrospective data of the study
sample stems from four outpatient specialized ASD
clinics in Germany where gold standard diagnostic pro-
cedures have been used to confirm the diagnosis of ASD
in 1359 individuals. An almost equal number (N = 1209)
of patients underwent the same procedures, but ASD
was ruled out leading to differential diagnoses (e.g.
ADHD, language disorder). The outlined machine learn-
ing methods (Decision Tree) as well as Support Vector
Machine analyses will be used to develop algorithms for
screening purposes. For these analyses the software
“Konstanz Information Miner (KNIME) 1 Analytics Plat-
form version 3.1.1” is used. The dataset will be divided
into training sets and test sets. To avoid overfitting
cross-validation will be performed and the dataset will
be split into five subsets. Four training sets will be used
to build the model. With the test set we will measure
the performance of the model. By performing several it-
erations, this method systematically uses another subset
for testing in each iteration. In doing so, the accuracy es-
timation is computed over multiple test sets. In a second
step, the developed algorithm will be tested in a com-
pletely independent sample of new-incident individuals
with suspected ASD.
On the basis of this large, well-characterized sample,
further analyses will be undertaken to improve the ef-
ficiency of diagnostic procedures. For this purpose,
sub-phenotype identification of ASD will be examined
with machine learning techniques. With the help of
exploratory and confirmatory factor analysis, the fac-
tor structure of algorithm items from the diagnostic
instruments will be examined and confirmed in order
to identify separable dimensions of the ASD sympto-
mology. To explore the overlap of symptoms of ASD
with other disorders, parent-reported and directly ob-
servable ASD symptoms will be compared between in-
dividuals who did and did not receive a diagnosis of
ASD. Group comparisons using analysis of variance
(ANOVA) as well as analyses of covariance (ANCOVA,
co-varying for age, intelligence) will be undertaken.
Thus, we hope to identify diagnostic elements that
show both a shifted distribution by diagnostic group
and also diagnostic items that differentiate best be-
tween ASD and specific non-ASD groups.
Additionally, we will collect and store biomaterial from
Germany’s largest cohort of individuals with ASD for
intended genetic analyses. In particular, analyses for can-
didate genes which are known to be involved in the
OXT pathway (e.g. OXTR, LNPEP, AVP, CD38) will be
undertaken.
Therapy cluster
Oxytocin-induced enhancement of SST in ASD (clinical trial)
This randomized, placebo-controlled, double-blind clin-
ical trial aims to test the effectiveness of OXT in enhan-
cing the acquisition of social skills during standardized
group-based social skills training (SST) and to test the
effectiveness of OXT in maintaining acquired social
skills over time. N = 168 children and adolescents with
ASD aged 8–18 years will be included. Inclusion criteria
are: diagnosis of high-functioning autism (F84.0 accord-
ing to ICD-10), Asperger syndrome (F84.5), atypical aut-
ism (F84.1), male patients, and age 12 ≤ years ≤18.
Exclusion criteria are: IQ < 75, obsessive-compulsive dis-
order, psychotic disorder, major depressive episode with
suicidal ideation, aggressive behavior interfering with
group therapy, any personality disorder, neurological dis-
order, cardiovascular and endocrinological disorder,
hypersensitivity to OXT, other medical disorder interfer-
ing with therapy, and group-based SST during the last
6 months prior to study.
Figure 1 describes the design of the trial. In a random-
ized, placebo-controlled, double-blind clinical trial, par-
ticipants will receive either OXT or placebo in the form
of intranasal spray in addition to group-based SST of 12
weekly sessions based on a manualized group therapy
program for ASD [58]. After consent is given, the initial
screening will begin in order to clarify inclusion and ex-
clusion criteria, encompassing the DIPS (Diagnostic
Interview for Children and Youth for DSM-IV) in order
to assess comorbid conditions. This will also comprise
saliva samples (cheek swabs) as well as comprehensive
medical evaluation including electrocardiogram. After
excluding cardiovascular diseases, every ASD patient will
receive an intranasal test dose of OXT under the control
of a physician (18 IU OXT for age 12–15 or 24 IU for
age 16–18). In the case of adverse side effects, patients
will be monitored by a physician and excluded from the
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study. Subsequently, patients with ASD will be randomly
assigned to the OXT group or to the placebo group.
Group therapists, participants and caregivers will be
blind to the participants’ allocation to OXT or placebo.
Baseline assessment (T1) will include administration of
questionnaires and tests assessing measures of primary
and secondary endpoints; demographic variables and sal-
iva samples will also be collected. During the following
12 weeks, group-based SST will be conducted in weekly
sessions delivered in combination with OXT or placebo
administered 40 min prior to each group-based SST, re-
spectively. SST will be delivered by trained behavioral
therapists in groups of 5–6 participants with ASD. Each
SST session will be structured and will follow a standard
sequence of activities, including introduction of a spe-
cific skill, modeling of the skill, role playing with re-
hearsal/ practice of the modeled skill, discussion, and
individualized performance feedback. Common topics
will include emotion recognition and regulation, social
competence, social problem solving, and social commu-
nication. Post-assessment (T2) will include identical
measures to at baseline (T1). Follow-up 1 (T3, 3 months
after the end of treatment) and follow-up 2 (T4,
6 months after the end of treatment) will again assess
the primary and secondary outcome measures. Primary
efficacy endpoints are changes in the total raw score of
the Social Responsiveness Scale (SRS) [83] rated by par-
ents between baseline assessment (T1), post-assessment
(T2), follow-up 3 months after end of intervention (T3)
and follow-up 6 months after end of intervention (T4).
Secondary endpoints are changes in the total raw score
of: (1) prosocial behavior and peer relationship problems
(SDQ) [84], (2) empathy (Multifaceted Empathy Test,
MET-J) [85], (3) depression (DIKJ) [86], (4) psycho-
logical distress (SSKJ) [87], (5) physiological distress
(cortisol levels), and (6) quality of life (CHIP-CE) [88].
An effect for OXT vs. placebo of d = 0.60 was calcu-
lated based on studies which included patients with
Fig. 1 Trial flow. Randomized, placebo-controlled, double-blind clinical trial with 5 phases of examination: T0) Screening; T1) Baseline, 12 weekly
SST in combination with OXT vs. 12 weekly SST without OXT; T2) Post-assessment; T3) Follow-up 3 months after end of treatment; T4) follow-up
6 months after end of treatment
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ASD. Since in the present study, an additional SST is in-
cluded for both groups, a more conservative effect of
d = 0.45 is assumed as realistic and clinically relevant.
Using a two-sample t-test with a two-sided significance
level of 5%, a total of 158 patients is required for the
analysis to achieve a power of 80% (nQuery Advisor 7.0).
Due to an expected drop-out rate of 5% and assuming
that 20% of screened patients are not eligible, N = 210
patients will be assessed for eligibility, of whom n = 168
patients will be allocated to either the OXT or placebo
group providing at least the desired power of 80%.
A confirmatory analysis of the primary efficacy end-
point will be conducted. Analysis of covariance
(ANCOVA) will be applied including baseline SRS total
raw score, age and IQ as continuous covariates and
center, comorbidity and medication status as factors for
control. Three primary endpoints are of interest and
hence three null hypotheses are tested. To ensure a
multiple type I error rate of 5%, a hierarchical test pro-
cedure will be applied: The first null hypothesis states
that the change in the total raw score of the SRS be-
tween T1 and T2 is equal for both groups (H01:
μT = μC) and is tested at a two-sided significance level
of 5% against the alternative hypothesis (H01: μT ≠ μC).
If the first null hypothesis can be rejected, the second
null hypothesis for the change in the SRS total raw
score between T1 and T3 will be tested again at a sig-
nificance level of 5%. Finally, if the second null hypoth-
esis can be rejected, the third null hypothesis for the
change in the SRS total raw score between T1 and T4
will be tested at a significance level of 5%. All second-
ary outcomes including safety data will be evaluated de-
scriptively, using appropriate statistical methods based
on the underlying distribution of the data. Descriptive
p-values are reported together with 95% confidence in-
tervals for the corresponding effects. Missing values
concerning primary outcomes are dealt with by applica-
tion of the mixed-effects model for repeated measures,
which turned out to show favourable characteristics in
terms of type I error rate, power, and bias of estimates
as compared to alternative methods dealing with miss-
ing values, such as last-observation-carried-forward
(LOCF). Missing values for the covariates will be re-
placed by multiple imputations.
This clinical trial will be conducted and analyzed in ac-
cordance with ICH-GCP guidelines, the Declaration of
Helsinki, German Drug Law (AMG) and Data Protection
Law. The trial including consent procedures been approved
by the leading ethics committee of Heidelberg University
and by the Federal higher authority (Federal Institute for
Drugs and Medical Devices, BfArM). All Parents/caregivers
gave written informed consent, minor participants gave
assent for participation in the study. It is registered in the
German Clinical Trials Register (DRKS00008952).
Neurobiological markers for SST response in ASD
This study is a supplement to the study outlined above
and is based on the assumption that effects of an OXT-
enhanced SST should be particularly observable in brain
regions associated with ASD and OXT like the social
brain (temporoparietal junction, temporal pole, precu-
neus and medial prefrontal cortex), reward circuits and
the amygdala [89]. We will therefore apply a battery of
three experimental fMRI tasks to examine the effect of
OXT administration on neural activation in N = 100
patients involved in the above-mentioned clinical trial
before and after SST. We will focus on the aforemen-
tioned brain regions and use fMRI paradigms which tar-
get these regions and functions. Moreover, we will
delineate OXT-specific modulation of the social brain
using a Theory of Mind (ToM) task to activate the men-
talizing network [90], an affective matching task focusing
particularly on the amygdala [91], and an adapted ver-
sion of a validated reward task combining both social
and non-social cues as well as social and non-social
rewards [92]. MR sequence protocols and stimulus pres-
entation settings have been harmonized across the two
participating sites. The main outcome variables will be
neural activity in and connectivity between the afore-
mentioned brain regions of interest during the three
tasks. Behavioral data such as accuracy ratings and re-
sponse times will also be used. We will identify specific
neurobiological mechanisms associated with therapy
response as well as particular neurobiological signatures
before treatment that are associated with treatment re-
sponse. Results should further allow us to develop hy-
potheses regarding how to tailor treatment to different
subtypes of ASD and to correctly allocate individuals to
treatment settings.
We assume an effect size of d = .45. Given a sample
size of 90 (100 minus 10% drop out), we have 85% power
to detect a difference (pair-wise t-test) at a significance
level of p < .001, which is a threshold often used for
whole brain fMRI studies.
Preprocessing and analysis of functional and structural
images will be processed using SPM12 toolbox (http://
www.fil.ion.ucl.ac.uk/spm/) within the Nipype frame-
work (http://nipy.org/nipype/). The quality of the fMRI
data will be ensured by manual inspection, using artifact
detection tools (ART) and a stringent motion control
procedure. To account for group-specific structural
brain difference a specific DARTEL template will be cre-
ated [93]. The slice time corrected functional data will be
realigned, registered, and normalized to MNI using the
DARTEL template. Whole brain data (or extracted sum-
mary metrics) will be compared using linear mixed effects
(LME) models with random intercepts, treatment as be-
tween- and timepoint as the within-subject factor. We will
covary for age and other possibly confounding variables.
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Modulatory effects of acute OXT treatment in ASD
(clinical trial)
This clinical study is a randomized, double-blind, cross-
over, placebo-controlled, multicenter functional mag-
netic resonance imaging study with two arms [94]. The
aim is to characterize the acute effects of OXT on neural
network activity during socio-affective and socio-
cognitive functioning in ASD and to compare these to
healthy controls (HC). A sample of 102 male ASD pa-
tients (age 19 ≤ years ≤40) diagnosed with Childhood
Autism (F84.0 according to ICD-10), Asperger syndrome
(F84.5 according to ICD-10), or atypical autism (F84.1
according to ICD-10) will be recruited. These will be
matched (IQ and age) with healthy control participants
(N = 66). Both groups will receive OXT and placebo
nasal spray on two different days at an interval of two
weeks to ensure a sufficient wash-out time after OXT
treatment. Both ASD patients and healthy control partic-
ipants will be randomized to determine whether they
receive OXT on the first or the second visit. Investiga-
tors and participants will be blind to the study condition.
Exclusion criteria are: IQ < 70; traumatic lesions of the
brain; serious neurological diseases (e.g. epilepsy); con-
traindications for OXT administration (e.g. known meta-
bolic or endocrinological disorders; cardiac disorders;
known hypersensitivity to nasal sprays or other drugs);
contraindications for the MRI assessment (e.g. incorpo-
rated metal, agoraphobia); comorbid drug or alcohol
abuse or dependence. In two consecutive sessions, ASD
patients and HC will receive 24 IU of OXT or placebo
as intranasal spray 45 min prior to the fMRI assessment
of activity in neural networks associated with social pro-
cesses. MRI assessment will last for 60 min and will en-
compass three experimental paradigms that probe
neural activation in social brain systems that have shown
altered activity in ASD in previous studies (emotional
matching [adapted from: [91]], social orienting, social
reward anticipation and consumption [adapted from:
[95, 96]], empathy, compassion and Theory of Mind
[adapted from: [97, 98]]), a resting state and structural
scans.
The primary outcome will be neural network activity,
measured with functional magnetic resonance imaging
while participants perform socio-affective and socio-
cognitive tasks. Secondary outcome measures will con-
sist of behavioral and physiological measures respectively
which comprise accuracy ratings and response times in
the conducted tasks (e.g. Theory of Mind task) as well
as skin conductance. Complementing performance,
descriptive measures of trait alexithymia, interpersonal
reactivity and social anxiety will be evaluated. Addition-
ally, the effect of OXT receptor gene variants its poten-
tial influence on the primary and secondary outcome
measures will be analyzed. Effect size of d = 0.65 will be
detected with 80% power and a significance level of
p = 0.001 (corrected) with a total sample size of 88 pa-
tients with ASD. With a drop-out estimation of 13%,
N = 102 patients have to be recruited as well as a
matched control group of healthy controls N = 88).
All fMRI data will be pre-processed and analyzed in
the statistical parametric mapping framework (SPM,
www.fil.ion.ucl.ac.uk/spm). Standard routines and
templates will be used for the fMRI data analysis and
pre-processing. BOLD activation will be analyzed with
a repeated measures analysis of variance (ANOVA) to
compare the effects of OXT treatment to placebo in
the ASD group. An independent samples t-test will be
conducted to compare neural network activity of ASD
patients to those of the HC group under placebo as
reference. Further, to characterize OXT effects in the
HC group and test for different treatment responses in
ASD patients and HCs, repeated measures ANOVA
will be conducted. To control for the increased type 1
error in the analysis of the imaging data, corrections
for multiple-comparisons will be applied as imple-
mented in SPM based on the estimated smoothness of
the statistical map using Gaussian random-field theory,
and the T and F maps will be thresholded accordingly.
Thresholding of the imaging data will be conducted in
two consecutive steps, first as an exploratory analysis
within the whole brain, and second within the predefined
regions of interest.
This clinical trial will be conducted in accordance with
ICH-GCP guidelines and the Declaration of Helsinki.
The trial has been approved by the leading ethics com-
mittee of Lübeck University, the concomitant ethical
board of Leipzig and the Federal higher authority (Fed-
eral Institute for Drugs and Medical Devices, BfArM).
Prior to testing, participants’ written informed consent
will be acquired. Consent procedures have been ap-
proved by the leading ethics committee. The trial is
registered in the German Clinical Trials Register
(DRKS00010053).
(Epi)genetics
Little is known about the molecular mechanisms under-
lying the impact of OXT on a behavioral and/or neural
level. In view of the individual variability in OXT re-
sponse, the consideration of individual factors such as
gender and genetic and epigenetic variations is war-
ranted in studies investigating the efficacy of OXT ad-
ministration in ASD treatment [65]. We will collect and
store biomaterial including pre−/post-treatment bioma-
terial information of participants involved in the above-
mentioned clinical trials. In this way, we aim to identify
genetic and epigenetic factors that are a) predictive at
baseline for the patients’ treatment [OXT, social skills
training (SST) + placebo, SST + OXT] outcome and b)
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associated with the response to acute and long-term
OXT administration. By identifying implicated genetic
factors and methylation changes, we will c) gain new in-
sights into the molecular mechanisms underlying ASD
and the OXT response. Data at baseline and after treat-
ment will be analyzed not only with respect to the cat-
egorical diagnoses but also regarding behavioral and
neuroimaging sub-phenotypes.
Health economics cluster
WP1 Cost-of-illness study. Using the Client Service Re-
ceipt Inventory (CSRI), we will collect data on service
utilization in a large sample of ASD patients (N = 1419)
in order to assess direct and indirect ASD-related costs.
An extensive literature review will be carried out to
gather information on services used and costs of each
service unit (e.g. CAM, special education lessons). Based
on these data, we will calculate annual and lifetime
ASD-related costs from a societal perspective (including,
e.g., education costs and parental productivity loss),
using a micro-costing approach, stratified by age, gender,
and IQ. WP2 Decision-analytic model: We will perform
an extensive literature review, with a focus on therapy
results and consistency of therapy outcomes in the ad-
dressed age group. On this basis, a decision-analytic
Markov model will be formed [78], simulating early
therapeutic interventions before vs. after five years of
age in ASD patients. Using a cost-benefit approach, po-
tential short-term and long-term cost effects will then be
calculated. WP3 Health services utilization pathway:
Using data from the total sample as well as a sub-sample
of patients from WP1 (new-incident ASD patients), we
will assess diagnostic pathways and barriers to service
utilization in patients with a first-time ASD diagnosis.
Based on these data, we aim to identify subgroups of
patients with differential needs, and suggest stratified
diagnostic and therapeutic pathways, with the objective
of more efficient resource utilization. Age and gender as-
pects, socioeconomic status and ASD-related stigma will
be addressed in all work packages, as these factors po-
tentially influence both diagnostic pathways and subse-
quent service utilization.
Standardised data collection forms will be used and
data will be entered in a Case Report Forms (CRF) cre-
ated in OpenClinica®. Mainly descriptive statistics will be
used for analyses on health services use. Prevalences
(e.g. on use of CAM use) alongside with 95% confidence
intervals will be calculated for dichotomous variables
and means (with standard deviation) or median (with
interquartile range) will be presented for continuous var-
iables (e.g. number of hospital days). Unadjusted indi-
vidual total costs will be calculated for each participant
by summing up costs of all categories. Relative differ-
ences in mean costs between groups (e.g. between
different age groups) will be assessed by using a
gamma-regression with log-link.
Discussion
In the present paper, we have identified a number of ur-
gent research questions in different areas of ASD re-
search. The ASD-net will address these questions in the
area of diagnosis, therapy and health economics and
thereby provide new insights that should improve early
diagnosis and treatment of the disorder and help to eco-
nomically optimize their application. However, in the
following section, we also wish to discuss some critical
aspects that we need to take into account when conduct-
ing our research program.
Diagnostic cluster
Machine learning is deemed to have great potential to
enhance diagnostic and interventional research and to
be especially useful in investigations involving the rela-
tively prevalent and heterogeneous syndrome of ASD
[99]. However, there are relevant critical aspects to be
considered when applying machine learning techniques
within the diagnostic process of ASD. Wall and col-
leagues [82] used machine learning to shorten the be-
havioral observation procedure (ADOS) by applying
machine learning techniques to automatically identify
the fewest number of items for an abbreviated algorithm.
In response, Bone et al. [99] argued that ADOS codes
might not be valid outside the context of a full ADOS
administration. In the light of the fact that administra-
tion time was not actually reduced with the approach
proposed by Wall et al. [82], the proposed procedure
seemed to be without benefit. Particularly as the input
data to the machine learning algorithms, i.e. the ADOS
codes are to be considered reliable and valid only when
educed by a specialist administrator using standardized
materials in the ADOS context, a semi-structured social
process. Furthermore, it was argued that the established
algorithms were not validated on independent data and
an adequate sample [80, 99]. It seems prudent to use lar-
ger and more balanced datasets, a more detailed
characterization of core ASD components from multiple
perspectives, and cross-validation in an independent
sample. Within the ASD-Net, these crucial aspects can
be resolved: In our large, well-characterized sample,
individual differences concerning age groups or other
sub-phenotypes can be detected and an evaluation in an
independent and clinical relevant sample is possible.
Given these circumstances, the aims of the diagnostic
cluster to develop and evaluate a screening instrument
for the early detection of ASD across all age ranges, IQ
ranges, and gender seems feasible. This will facilitate
early and effective access for affected individuals to spe-
cialized procedures and therapeutic interventions.
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Moreover, economical screening instruments will reduce
the increasing amount of health care utilization in terms
of time- and personnel-intensive diagnostic investiga-
tions and ultimately reduce the rate of false-positive and
false-negative cases. In turn, this will improve the effi-
ciency of diagnostic procedures over the lifespan and
consequently enhance the effectiveness of the health
care system.
Therapy cluster
Several studies have documented that intranasal OXT
shows promising effects: reduction of social fear and
stress and increase in trust, emotion recognition, Theory
of Mind, empathy and bonding behavior. Although clin-
ical trials of intranasal administration of OXT for treat-
ing psychiatric problems have yielded mixed results [61,
100–102], most authors conclude that intranasal admin-
istration of OXT is a potentially useful intervention for
the treatment of ASD [62, 63, 103]. Notably, a recently
published meta-analysis [64] summarized recent studies
on pharmacotherapeutic applications of OXT treatment
in order to explore its potential and limitations. It con-
cluded that studies on ASD showed significant effect
sizes (d = 0.57; N = 68; 95% CI: 0.15–0.99; p < 0.01). As
there is no effective medical treatment for the core ASD
symptoms, and psychological treatments remain costly,
time-intensive and developmentally sensitive in terms of
efficacy, OXT-based therapies may have the potential to
close this gap. However, more studies are needed that
determine the best treatment target and identify the
underlying mechanisms of behavioral change.
Evidence shows that acute OXT administration is asso-
ciated with changes in numerous markers critical to the
functioning of the brain circuitry underlying social defi-
cits in ASD [adapted from: [102, 104–106]], even though
the neural processes and the specificity of OXT effects
on socio-affective and socio-cognitive functioning are
not fully understood [59, 64, 101, 107, 108]. Although
recent evidence seems to suggest that OXT might
optimize neural transmission in socio-affective and
socio-cognitive brain circuits and enhance reward, mo-
tivation, and learning to improve therapeutic outcomes,
the current evidence regarding the therapeutic benefit
from extended OXT treatment remains very limited.
The very first studies investigating the efficacy, toler-
ability and safety of extended OXT treatment in individ-
uals with ASD produced mixed results: An Australian
study [109] examined the effect of OXT and placebo
nasal spray (24 IU per day) for 5 weeks and found that
OXT led to significant improvements in caregiver-rated
social responsiveness. In adults (N = 19), no significant
changes were observed in the primary outcome mea-
sures (social function/cognition and repetitive behaviors;
results suggested improvements after 6 weeks on
measures of social cognition). Two other studies found
no effect in youth with ASD [110], or of the long-term
administration of intranasal OXT in adolescent and
adult ASD subjects with intellectual disability (N = 29)
[111]. To date, only one pilot study has combined the
administration of OXT with behavioral treatment: 38
male youths (7–16 years old) with ASD received intrana-
sal OXT or placebo once daily over four consecutive
days during parent-child interaction training sessions
[112]. This very short intervention did not significantly
improve emotion recognition, social interaction skills, or
general behavioral adjustment. As the safety of OXT is
reported to be very good [113], but information on effi-
cacy, especially in children and adolescents with ASD, is
still limited and ambiguous, more elaborated clinical tri-
als with OXT are warranted [63], and the proposed study
protocol has the potential to address this need.
In summary, the aim of the therapy cluster is to
unravel whether and how combined behavioral and
pharmacological treatments modulate behavior through
neurobiological pathways in ASD. This is of central im-
portance for developing biologically plausible models
for the symptoms in the social domain and successful
future therapeutic interventions in ASD. In addition,
the acute effects of OXT administration on the neuro-
biology of social cognition will be tested. This will serve
as a basis from which to further disentangle the acute
and long-term effects of OXT on neurobiological path-
ways. The determination of characteristic biomarkers
for (sub-) phenotypes by integration of (epi)genetic,
behavioral and neuroimaging data may also help to pre-
dict treatment response early and allocate patients to
adequate treatments in order to minimize personal dis-
tress and financial resources. One potential challenge
lies in the recruitment of the required large sample of
adolescents. These have to be willing to participate in
the study, to take the time (besides, e.g., school, leisure
activities, special education) to attend at the same time
slots as other group members, have no (metal) retainers
or other dental braces, live near to the study centers or
have parents who can drive them to the study center
once a week.
Health economics cluster
The substantial burden of ASD on the public sector has
been documented for the USA and the UK. However,
data on ASD-related costs in Germany are lacking.
Thus, the main goal of the health economics cluster is
to assess the status quo in terms of resource allocation
and costs for ASD in Germany. This will help to identify
subgroups of ASD patients with differential needs, en-
able stratified diagnostic and therapeutic pathways for
ASD patients, and facilitate cost-saving resource alloca-
tion. Together, the results of this cluster have significant
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potential to improve health service utilization experi-
ences for patients with ASD and their caregivers, and to
optimize resource utilization in these patients.
Conclusions
In sum, the highly integrated structure of the ASD-Net
guarantees sustained collaboration of clinicians and re-
searchers to reduce individual distress, harm, and social
disability of patients and costs for the German health
care system. In light of the enormous burden ASD rep-
resents for concerned individuals, families and society as
a whole, a sustainable improvement in the financial sup-
port for those researching ASD is absolutely essential.
However, the greatest challenge will be the allotted dur-
ation for the ASD-Net, which seems to be a rather tight
schedule. The resources concerning personnel and time
are restricted, and an extension to continue after the
funded time period and extension of funding will most
likely be necessary.
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